Form 4: Arcutis Biotherapeutics Director Howard G. Welgus Reports Stock Transactions
SEC Form 4 Filing
Director Howard G. Welgus of Arcutis Biotherapeutics reports the exercise of stock options and subsequent sale of common stock on June 4, 2024.
Summary
- On June 4, 2024, Howard G. Welgus, a director of Arcutis Biotherapeutics, exercised stock options to acquire 3,542 shares at $1.6806 per share and 6,458 shares at $1.6806 per share.
- Simultaneously, Welgus sold 3,542 shares at $8 per share and 6,458 shares at a weighted average price of $8.0142 per share.
- Following these transactions, Welgus directly owns 170,200 shares of common stock and indirectly owns 24,991 shares through The Welgus Living Trust.
- Welgus also holds options to purchase 5,681 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports factual stock transactions without expressing any positive or negative outlook.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, providing transparency to the market regarding their investment activities.
Stakeholder Impact
- The transactions may provide insights to shareholders regarding the director's view on the company's stock value.
Key Dates
| Date | Description |
|---|---|
| 03/13/2029 | Expiration date of stock options |
| 06/04/2024 | Date of stock option exercise and stock sale transactions |
| 06/06/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.